Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma von Yang, Yibin, Shaffer, Arthur L., Emre, N.C. Tolga, Ceribelli, Michele, Zhang, Meili, Wright, George, Xiao, Wenming, Powell, John, Platig, John, Kohlhammer, Holger, Young, Ryan M., Zhao, Hong, Yang, Yandan, Xu, Weihong, Buggy, Joseph J., Balasubramanian, Sriram, Mathews, Lesley A., Shinn, Paul, Guha, Rajarshi, Ferrer, Marc, Thomas, Craig, Waldmann, Thomas A., Staudt, Louis M.

Volltext

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo von Ponader, Sabine, Chen, Shih-Shih, Buggy, Joseph J., Balakrishnan, Kumudha, Gandhi, Varsha, Wierda, William G., Keating, Michael J., O'Brien, Susan, Chiorazzi, Nicholas, Burger, Jan A.

Volltext

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies von ADVANI, Ranjana H, BUGGY, Joseph J, SUKBUNTHERNG, Juthamas, IZUMI, Raquel, HAMDY, Ahmed, HEDRICK, Eric, FOWLER, Nathan H, SHARMAN, Jeff P, SMITH, Sonali M, BOYD, Thomas E, GRANT, Barbara, KOLIBABA, Kathryn S, FURMAN, Richard R, RODRIGUEZ, Sara, CHANG, Betty Y

Volltext

Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy von Honigberg, Lee A, Smith, Ashley M, Sirisawad, Mint, Verner, Erik, Loury, David, Chang, Betty, Li, Shyr, Pan, Zhengying, Thamm, Douglas H, Miller, Richard A, Buggy, Joseph J

Volltext

Isoform-specific histone deacetylase inhibitors: The next step? von Balasubramanian, Sriram, Verner, Erik, Buggy, Joseph J

Volltext

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia von de Rooij, Martin F.M., Kuil, Annemieke, Geest, Christian R., Eldering, Eric, Chang, Betty Y., Buggy, Joseph J., Pals, Steven T., Spaargaren, Marcel

Volltext

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 von Herman, Sarah E.M., Gordon, Amber L., Hertlein, Erin, Ramanunni, Asha, Zhang, Xiaoli, Jaglowski, Samantha, Flynn, Joseph, Jones, Jeffrey, Blum, Kristie A., Buggy, Joseph J., Hamdy, Ahmed, Johnson, Amy J., Byrd, John C.

Volltext

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial von O'Brien, Susan, Prof, Furman, Richard R, MD, Coutre, Steven E, Prof, Sharman, Jeff P, MD, Burger, Jan A, MD, Blum, Kristie A, MD, Grant, Barbara, MD, Richards, Donald A, MD, Coleman, Morton, Prof, Wierda, William G, MD, Jones, Jeffrey A, MD, Zhao, Weiqiang, MD, Heerema, Nyla A, Prof, Johnson, Amy J, PhD, Izumi, Raquel, PhD, Hamdy, Ahmed, MD, Chang, Betty Y, PhD, Graef, Thorsten, MD, Clow, Fong, ScD, Buggy, Joseph J, PhD, James, Danelle F, MD, Byrd, John C, Prof

Volltext

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells von Chang, Betty Y, Huang, Min Mei, Francesco, Michelle, Chen, Jun, Sokolove, Jeremy, Magadala, Padmaja, Robinson, William H, Buggy, Joseph J

Volltext

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination von Adimoolam, Shanthi, Sirisawad, Mint, Chen, Jun, Thiemann, Patti, Ford, James M, Buggy, Joseph J

Volltext

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma von Tai, Yu-Tzu, Chang, Betty Y., Kong, Sun-Young, Fulciniti, Mariateresa, Yang, Guang, Calle, Yolanda, Hu, Yiguo, Lin, Jianhong, Zhao, Jian-Jun, Cagnetta, Antonia, Cea, Michele, Sellitto, Michael A., Zhong, Mike Y., Wang, Qiuju, Acharya, Chirag, Carrasco, Daniel R., Buggy, Joseph J., Elias, Laurence, Treon, Steven P., Matsui, William, Richardson, Paul, Munshi, Nikhil C., Anderson, Kenneth C.

Volltext

The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss von Shinohara, Masahiro, Chang, Betty Y, Buggy, Joseph J, Nagai, Yusuke, Kodama, Tatsuhiko, Asahara, Hiroshi, Takayanagi, Hiroshi

Volltext

Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for Insulinoma von Soucek, Laura, Buggy, Joseph J, Kortlever, Roderik, Adimoolam, Shanthi, Monclús, Helena Allende, Allende, Maria Teresa Salcedo, Swigart, Lamorna Brown, Evan, Gerard I

Volltext

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia von Byrd, John C, Furman, Richard R, Coutre, Steven E, Flinn, Ian W, Burger, Jan A, Blum, Kristie A, Grant, Barbara, Sharman, Jeff P, Coleman, Morton, Wierda, William G, Jones, Jeffrey A, Zhao, Weiqiang, Heerema, Nyla A, Johnson, Amy J, Sukbuntherng, Juthamas, Chang, Betty Y, Clow, Fong, Hedrick, Eric, Buggy, Joseph J, James, Danelle F, O'Brien, Susan

Volltext

A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models von Willingham, Stephen B, Ho, Po Y, Hotson, Andrew, Hill, Craig, Piccione, Emily C, Hsieh, Jessica, Liu, Liang, Buggy, Joseph J, McCaffery, Ian, Miller, Richard A

Volltext

CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo von Buggy, Joseph J, Cao, Z Alexander, Bass, Kathryn E, Verner, Erik, Balasubramanian, Sriram, Liu, Liang, Schultz, Brian E, Young, Peter R, Dalrymple, Stacie A

Volltext

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes von Dubovsky, Jason A., Beckwith, Kyle A., Natarajan, Gayathri, Woyach, Jennifer A., Jaglowski, Samantha, Zhong, Yiming, Hessler, Joshua D., Liu, Ta-Ming, Chang, Betty Y., Larkin, Karilyn M., Stefanovski, Matthew R., Chappell, Danielle L., Frissora, Frank W., Smith, Lisa L., Smucker, Kelly A., Flynn, Joseph M., Jones, Jeffrey A., Andritsos, Leslie A., Maddocks, Kami, Lehman, Amy M., Furman, Richard, Sharman, Jeff, Mishra, Anjali, Caligiuri, Michael A., Satoskar, Abhay R., Buggy, Joseph J., Muthusamy, Natarajan, Johnson, Amy J., Byrd, John C.

Volltext

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma von Wang, Michael L, Rule, Simon, Martin, Peter, Goy, Andre, Auer, Rebecca, Kahl, Brad S, Jurczak, Wojciech, Advani, Ranjana H, Romaguera, Jorge E, Williams, Michael E, Barrientos, Jacqueline C, Chmielowska, Ewa, Radford, John, Stilgenbauer, Stephan, Dreyling, Martin, Jedrzejczak, Wieslaw Wiktor, Johnson, Peter, Spurgeon, Stephen E, Li, Lei, Zhang, Liang, Newberry, Kate, Ou, Zhishuo, Cheng, Nancy, Fang, Bingliang, McGreivy, Jesse, Clow, Fong, Buggy, Joseph J, Chang, Betty Y, Beaupre, Darrin M, Kunkel, Lori A, Blum, Kristie A

Volltext

Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity von Kohrt, Holbrook E., Sagiv-Barfi, Idit, Rafiq, Sarwish, Herman, Sarah E.M., Butchar, Jonathon P., Cheney, Carolyn, Zhang, Xiaoli, Buggy, Joseph J., Muthusamy, Natarajan, Levy, Ronald, Johnson, Amy J., Byrd, John C.

Volltext

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL) von Woyach, Jennifer A., Bojnik, Engin, Ruppert, Amy S., Stefanovski, Matthew R., Goettl, Virginia M., Smucker, Kelly A., Smith, Lisa L., Dubovsky, Jason A., Towns, William H., MacMurray, Jessica, Harrington, Bonnie K., Davis, Melanie E., Gobessi, Stefania, Laurenti, Luca, Chang, Betty Y., Buggy, Joseph J., Efremov, Dimitar G., Byrd, John C., Johnson, Amy J.

Volltext